Investigational drug · Phase 2
LS301-IT
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer (NSCLC), Breast Cancer, DCIS.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "LS301-IT"
First trial start
2023
Jul 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LS301-IT", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Small Cell Lung Cancer (NSCLC)
- Breast Cancer
- DCIS
- Invasive Duct Carcinoma of Breast
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LS301-IT" as an intervention, largest first.
- Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung CancerActive, not recruiting
Integro TheranosticsIndustry
NCT07276789 · 35 participants (planned) · Start Dec 8, 2025 · Primary completion Jun 2027
Drug: LS301-IT 0.1 mg/kg · For: Non Small Cell Lung Cancer (NSCLC)
Sites: Iowa City, Iowa; Philadelphia, Pennsylvania; Dallas, Texas
Integro TheranosticsIndustry
NCT06713564 · 24 participants · Start Nov 7, 2024 · Primary completion May 6, 2026
Drug: LS301-IT · For: Lung Cancers
Sites: Philadelphia, Pennsylvania
Integro TheranosticsIndustry
NCT05900986 · 22 participants · Start Jul 14, 2023 · Primary completion Oct 6, 2025
Drug: LS301-IT 0.025 mg/kg; LS301-IT 0.05 mg/kg and 2 more · For: Breast Cancer; DCIS; Invasive Duct Carcinoma of Breast
Sites: Scottsdale, Arizona; Washington D.C., District of Columbia; Weston, Florida · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non Small Cell Lung Cancer (NSCLC)
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
- WSD0922-FUWSD0922Phase 23 trials
Wayshine Biopharm, Inc. · Non Small Cell Lung Cancer (NSCLC), EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer
- AP203Phase 21 trial
AP Biosciences Inc. · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.